+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Primary prevention with statins and incident diabetes in hypertensive patients at high cardiovascular risk

Primary prevention with statins and incident diabetes in hypertensive patients at high cardiovascular risk

Nutrition, Metabolism, and Cardiovascular Diseases 23(11): 1101-1106

The ESC/ESH guidelines for arterial hypertension recommend using statins for patients with high cardiovascular (CV) risk for both secondary and primary prevention. A recent meta-analysis, combining previous studies on statins, concluded that they are associated with a 9% increased risk of incident type 2 diabetes mellitus (DM). There is no information on whether statins increase incidence of DM in primary prevention. We evaluated risk of incident DM in relation to statin prescription in 4750 hypertensive, non-diabetic outpatients (age 58.57 ± 9.0 yrs, 42.3% women), from the CampaniaSalute Network, without chronic kidney disease more than grade 3, free of prevalent CV disease and with at least 12 months of follow-up. DM was defined according to ADA criteria. At the end of follow-up period (55.78 ± 42.5 months), 676 patients (14%) were on statins. These patients were older (62.54 ± 7.3 vs 57.91 ± 9.1 yrs; p < 0.0001), more often female (49% vs 41.2%; p = 0.0001), with higher initial total cholesterol (217.93 ± 44.3 vs 205.29 ± 36.6 mg/dl), non-HDL cholesterol (167.16 ± 44.5 vs 155.18 ± 36.7 mg/dl) and triglycerides (150.69 ± 85.2 vs 130.98 ± 72.0 mg/dl; all p < 0.0001) than patients no taking statins, without other differences in clinical and laboratory characteristics. At the end of follow-up, prevalence of DM was 18.1% among patients on statins and 7.2% among those without lipid-lowering therapy (p < 0.0001). However, incident DM was 10.2% in patients on statins and 8.7% in those free of statin therapy (NS). In real-life outpatient environment, statin prescription for primary prevention is not associated with increased risk of incident DM.

(PDF emailed within 0-6 h: $19.90)

Accession: 036767643

Download citation: RISBibTeXText

PMID: 23419735

DOI: 10.1016/j.numecd.2012.11.002

Related references

Statins and all-cause mortality in high-risk primary prevention of patients with cardiovascular risk factors. Archives of Internal Medicine 170(22): 2041; Author Reply 2043-4, 2011

There is a slight increase in incident diabetes risk with the use of statins, but benefits likely outweigh any adverse effects in those with moderate-to-high cardiovascular risk. Evidence-Based Medicine 15(3): 84-85, 2010

Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece. Clinicoeconomics and Outcomes Research 4: 135-143, 2012

Risk-benefit analysis of use of statins for primary prevention of cardiovascular disease in subjects without diabetes. Journal of Diabetes Investigation 4(4): 344-346, 2014

Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 121(9): 1069-1077, 2010

Primary prevention of cardiovascular diseases with statins in patients with diabetes. Medicina Clinica 144(6): 285-287, 2015

Role of statins for the primary prevention of cardiovascular disease in patients with type 2 diabetes mellitus. American Journal of Health-System Pharmacy 64(15): 1603-1610, 2007

Statins Ineffective for Primary Prevention of Cardiovascular Disease in Patients 75 Years or Older Without Diabetes Mellitus. American Family Physician 99(7): 461, 2019

Cardiovascular risk stratification in overweight or obese patients in primary prevention. Implications for use of statins. Endocrinologia Y Nutricion 62(2): 83-90, 2016

Statins and risk of treated incident diabetes in a primary care population. British Journal of Clinical Pharmacology 75(4): 1118-1124, 2013

Efficacy of aspirin and statins in primary prevention of cardiovascular mortality in uncomplicated hypertensive participants. Journal of Hypertension 35: S33-S40, 2017

Clinical significance of mild lipid-lowering by statins for prevention of cardiovascular disease in Japanese high-risk patients. Circulation Journal 74(4): 630-631, 2010

Influence and critique of the JUPITER Trial (Statins v no statins for primary prevention of cardiovascular events in patients with normal lipids and elevated C-reactive protein). Seminars in Vascular Surgery 24(3): 172-179, 2012

Primary cardiovascular prevention with statins in type 2 diabetes mellitus. Medicina Clinica 144(9): 431-432, 2016

Relevance of diabetes in high cardiovascular risk hypertensive patients. Medicina Clinica 141(7): 287-291, 2014